(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
5 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 10.87%
@ $93.66
発行日: 27 4月 2024 @ 03:20
リターン: -0.70%
前回のシグナル: 4月 26 - 01:08
前回のシグナル:
リターン: 3.76 %
Live Chart Being Loaded With Signals
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 710 386 |
平均出来高 | 805 482 |
時価総額 | 5.69B |
EPS | $0 ( 2024-02-15 ) |
次の収益日 | ( $-1.640 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.11 |
ATR14 | $4.51 (4.85%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-28 | Landsittel Michael | Buy | 5 000 | Common Stock |
2024-03-28 | Landsittel Michael | Sell | 5 000 | Common Stock |
2024-03-28 | Landsittel Michael | Sell | 5 000 | Stock Option (Right to Buy) |
2024-03-07 | Albers Jeffrey W. | Sell | 11 033 | Common Stock |
2024-03-20 | Albers Jeffrey W. | Buy | 10 000 | Common Stock |
INSIDER POWER |
---|
36.49 |
Last 100 transactions |
Buy: 596 437 | Sell: 283 237 |
ボリューム 相関
Blueprint Medicines Corp 相関
10 最も負の相関 | |
---|---|
PEAR | -0.951 |
VORB | -0.949 |
INFN | -0.934 |
MKTX | -0.931 |
BHTG | -0.928 |
FEMY | -0.927 |
IVAC | -0.926 |
EDUC | -0.926 |
TRIT | -0.925 |
OBNK | -0.924 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Blueprint Medicines Corp 相関 - 通貨/商品
Blueprint Medicines Corp 財務諸表
Annual | 2023 |
収益: | $249.38M |
総利益: | $224.92M (90.19 %) |
EPS: | $-8.37 |
FY | 2023 |
収益: | $249.38M |
総利益: | $224.92M (90.19 %) |
EPS: | $-8.37 |
FY | 2022 |
収益: | $204.04M |
総利益: | $186.22M (91.27 %) |
EPS: | $-9.35 |
FY | 2021 |
収益: | $180.08M |
総利益: | $162.15M (90.04 %) |
EPS: | $-11.81 |
Financial Reports:
No articles found.
Blueprint Medicines Corp
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。